Decreasing interleukin-6 levels after TIPS predict outcomes in decompensated cirrhosis
Systemic inflammation is a major driver of disease progression in patients with decompensated advanced chronic liver disease (dACLD). This study demonstrates that systemic inflammation (<i>i.e.</i> interleukin-6 [IL-6]) effectively and sustainedly decreases after transjugular intrahepatic portosystemic shunt (TIPS) implantation. A decrease of IL-6 3 months after TIPS implantation is a protective factor for acute-on-chronic liver failure and liver-related death. Thus, our results suggest that TIPS reduces systemic inflammation in a clinically meaningful way.
Authors
- Mattias Mandorfer (ORCID: https://orcid.org/0000-0003-2330-0017)
- Lena Stockhoff (ORCID: https://orcid.org/0000-0002-8453-8603)
- Lukas Reider
- Nina Dominik (ORCID: https://orcid.org/0009-0009-4615-915X)
- Lukas Hartl (ORCID: https://orcid.org/0000-0003-3398-6120)
- Benjamin Maasoumy (ORCID: https://orcid.org/0000-0002-3250-3177)
- Christine S. Falk (ORCID: https://orcid.org/0000-0003-1376-7318)
- Julia Kappel
- Andrea Kornfehl
- Hannah Rieland (ORCID: https://orcid.org/0000-0002-4906-3948)
- Thomas Reiberger (ORCID: https://orcid.org/0000-0002-4590-3583)
- Theresa Bucsics (ORCID: https://orcid.org/0000-0003-3901-4111)
- Michael A Trauner (ORCID: https://orcid.org/0000-0002-1275-6425)
- Paul Hemetsberger
- Anja Tiede
- Georg Kramer (ORCID: https://orcid.org/0009-0008-1736-3699)
Institutions
- Medizinische Hochschule Hannover (DE)
- German Center for Infection Research (DE)
- Marienhospital Osnabrück (DE)
- Medical University of Vienna (AT)
Publication Details
- Journal
- JHEP Reports
- Published
- 2024-12-18
- DOI
- https://doi.org/10.1016/j.jhepr.2024.101308
- Citations
- 15
- Primary Topic
- Liver Disease and Transplantation
- Type
- article
- Field-Weighted Citation Impact
- 5.54
Funders
- GlaxoSmithKline
- Gilead Sciences
- Alnylam Pharmaceuticals
- Ultragenyx Pharmaceutical
- Ipsen
- Norgine